Region Stockholm – SLSO — Clinical Trial Site

63 Registered trials

26 Currently recruiting

Organisation

Region Stockholm – SLSO

Location

Stockholm, Sweden

Identifier

ORG-100042877

Address

Solnavagen 1 E, S:t Matteus, 113 65, Sweden

Departments

"Studieenheten Akademiskt Specialistcentrum Sabbatsbergs sjukhus Dalagatan 9, entréplan"
#2403:Centrum för Neurologi
#4300: Centrum för reumatologi
#5300: Centrum för neurologi
4300:Centrum för reumatologi
Academic Specialist Center Study Unit, Dalagatan 9, Sabbatsbergs sjukhus, 113 61 Stockholm
Academic Specialist Center, SLSO
Akademiskt specialistcentrum
Akademiskt Specialistcentrum, Centrum för Diabetes
Akademiskt Specialistcentrum, Centrum för Neurologi
ALS Clinic Karolinska University Hospital
Aune Avik Akademiskt specialistcentrum Centrum för Reumatologi
Avdelningen för hematologi
Barncanceravdelningen
Beroendecentrum
Beroendecentrum Stockholm
Center for Neurology (KI)
Centrum för allogen Stamcellstransplantation
Centrum för diabetes
Centrum för diabetes, Akademiskt specialistcentrum, Solnavagen 1E, plan 5, 113 65 Stockholm
Centrum för diabetes, Norrbackagatan 90, Plan 5, 113 65 Stockholm
Centrum för Diabetes, Solnavägen 1E, 113 65 Stockholm
Centrum för diabetes, Solnavägen 1e, 11365 Stockholm
Centrum för neurologi
Centrum för neurologi, Akademiskt specialistcentrum
Centrum för reumatologi
Citydiabetes Serafen, Hantverkargatan 2D, 112 21 Stockholm
Department of Clinical Neuroscience, Norra stationsgatan 69, 113 64 Stockholm
Department of Neurology
Gastro Hud Reuma
Handens vårdcentral, Dalarövägen 6, 136 46 Handen
Hematology
Infectious Diseases
Karolinska Institutet
Medicinmottagning 5/Överviktsenheten
Mottagning för Hjärnstimulering, Norra Stockholms Psykiatri, SLSO
N/A
Neurologkliniken
Neurologkliniken + Centrum för neurologi
Neurology
Psykiatri Nordväst, Danderyds sjukhus
Psykiatri Södra Region Stockholm, Lasarettsvägen 6, 131 45 Nacka
Reumatologi kliniken
S:t Görans sjukhus, Norra Stockholms psykiatri, SLSO, Region Stockholm
Specialistpsykiatrisk mottagning 2, Norra Stockholms psykiatri, Box 618. SE-113 21 Stockholm
Stockholms läns sjukvårdsområde
Studieenheten Academic Specialist Center
Studieenheten Akademiskt Specialistcentrum
Studieenheten Akademiskt Specialistcentrum, Dalagatan 9
Studieenheten Akademiskt Specialistcentrum, Dalagatan 9, 113 61 Stockholm
Studieenheten Akademiskt specialistcentrum, Dalagatan 9, 11361 Stockholm
Studieenheten Akademiskt Specialistcentrum, ME Neurlogi
Studieenheten Akademiskt Specialistcentrum, Sabbatsberg Närsjukhus, 11361 Stockholm
Studieenheten Akademiskt specialistcentrum, Sabbatsbergs Sjukhus, Dalagatan9, 113 61 Stockholm
Studieenheten Akademiskt specialistcentrum, SLSO
Studieenheten, Akademiskt specialistcentrum (SLSO) Dalagatan 9 113 61 Stockholm Sweden
Visby Hospital, Dep. of Obstetrics and Gynecology, St. Göransgatan 5, 62155 Visby

Clinical trials at this site (63)

Search interface

A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended

2024-511557-21-00 Major Depressive Disorder (MDD) with Moderate-to-severe 5 2024-11-14
A safety and efficacy study of ARGX-119 in adult patients with Amyotrophic Lateral Sclerosis (ALS) (reALiSe) Ended

2024-511318-19-00 Amyotrophic Lateral Sclerosis (ALS) 4 2024-10-23
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dos… Ended

2023-506000-50-00 Adult Patients with Moderate-to-Severe Asthma Uncontrol 4 2024-09-26
A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni… Ended

2023-505755-40-00 Chronic kidney disease 4 2024-08-16
AMX0035 and Progressive Supranuclear Palsy Ended

2023-505893-14-00 Progressive Supranuclear Palsy 5 2024-06-04
Long Term Outcomes Ended

2023-505098-34-00 Opioid Use Disorder 6 2024-04-22
A24110He in a placebo-controlled trial evaluating safety in subjects with elevated plasma triglycerides Ended

2023-509091-42-00 Moderate to severe hypertriglyceridemia 4 2024-02-27
A study to test whether BI 456906 helps people living with overweight or obesity who do not have diabetes to lose weight Ended

2022-502529-17-00 Obesity 5 2024-01-18
A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight Ended

2022-502531-18-00 Obesity 5 2024-01-18
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a… Ended

2022-501895-25-00 Polymyalgia Rheumatica 5 2023-09-13
A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression. Ended

2023-508163-74-00 Major Depressive Disorder 5 2023-06-12
A clinical study to investigate if the investigational drug Diamyd is safe and can preserve insulin production and secretion in adolescents … Ended

2024-513304-33-00 Type 1 diabetes mellitus 5 2022-03-17
A Phase 2a study to evaluate, safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with amyotrophic lat… Ended

2024-512343-23-00 Amyotrophic Lateral Sclerosis (ALS) 4 2022-01-12
A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral Sclerosis Ended

2023-508511-23-00 Amyotrophic Lateral Sclerosis (ALS) 5 2021-12-02
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la … Ended

2023-506543-41-00 Multiple sclerosis (MS) 5 2018-07-25